脂肪原/白僵菌素/AG-CN2-0043-M001/1毫克
商品编号：
AG-CN2-0043-M001
品牌：
Adipogen Inc
市场价：
¥800.00
美元价：
480.00
产品分类：
其他试剂
公司分类：
Other_reagents
联系Q Q：
3392242852
电话号码：
4000-520-616
电子邮箱：
info@ebiomall.com
商品介绍
| ProductDetails | |
|---|---|
| ProductType | Chemical |
| Properties | |
| Formula | C45H57N3O9 |
| MW | 784.0 |
| CAS | 26048-05-5 |
| Source/HostChemicals | IsolatedfromfungusBeauveriasp. |
| PurityChemicals | ≥97%(HPLC) |
| Appearance | Whitetooff-whitesolid. |
| Solubility | Solubleinethanol,methanolorDMSO. |
| Identity | Determinedby1H-NMR. |
| Declaration | ManufacturedbyBiOlinksK.K.withcourtesystrainfromTheKitasatoInstitute. |
| InChiKey | GYSCAQFHASJXRS-GCXUEHFUSA-N |
| ShippingandHandling | |
| Shipping | AMBIENT |
| ShortTermStorage | +4°C |
| LongTermStorage | -20°C |
| HandlingAdvice | Keepcoolanddry. Protectfromlight. |
| Use/StABIlity | Stableforatleast2yearsafterreceiptwhenstoredat-20°C. Storesolutionsat-20°Cinthedark. |
| Documents | |
| MSDS |  DownloadPDF |
| ProductSpecificationSheet | |
| Datasheet | DownloadPDF |
- Antibiotic[4].Mycotoxin.
- Apoptosisinducer[1,3,8,9,18].
- Acyl-CoA:cholesterolacyltransferase(ACAT)inhibitor[2].
- Anticancercompound[3,7,9].
- Antihaptotacticandantimetastatic[10].
- Antiangiogeniccompound[10].
- Antibacterial,antiprotozal,antiviralandantifungalcompound[4,11,13,15,16].
- Showsionophoricproperties[5,17].
- Cytotoxic[6,7].
- Genotoxic[14].
- PotentlyinteractswithABCB1andABCG2transportfunctions[12].
- Causesmitochondrialdysfunction[17].
ProductReferences
- Ionophore-inducedapoptosis:roleofDNAfragmentationandcalciumfluxes:D.M.Ojcius,etal.;Exp.CellRes.197,43(1991)
- Inhibitionofacyl-CoA:cholesterolacyltransferaseactivitybycyclodepsipeptideantibiotics:H.Tomoda,etal.;J.Antibiot.(Tokyo)45,1626(1992)
- Bcl-2isoverexpressedandaltersthethresholdforapoptosisinacholangiocarcinomacellline:D.M.Harnois,etal.;Hepatology26,884(1997)
- AntimycobacterialandantiplasmodialcyclodepsipeptidesfromtheinsectpathogenicfungusPaecilomycestenuipesBCC1614:C.Nilanonta,etal.;PlantaMed.66,756(2000)
- Beauvericin-inducedchannelsinventricularmyocytesandliposomes:K.Kouri,etal.;Biochim.Biophys.Acta.1609,203(2003)
- Cytotoxiceffectsofthemycotoxinbeauvericintohumancelllinesofmyeloidorigin:L.Calò,etal.;Pharmacol.Res.49,73(2004)
- Beauvericininducescytotoxiceffectsinhumanacutelymphoblasticleukemiacellsthroughcytochromecrelease,caspase3activation:thecausativeroleofcalcium:G.M.Jow,etal.;CancerLett.216,165(2004)
- InvolvementofBcl-2family,cytochromecandcaspase3ininductionofapoptosisbybeauvericininhumannon-smallcelllungcancercells:H.I.Lin,etal.;CancerLett.230,248(2005)
- Inductionofcalciuminfluxfromextracellularfluidbybeauvericininhumanleukemiacells:B.F.Chen,etal.;BBRC340,134(2006)
- Searchforcellmotilityandangiogenesisinhibitorswithpotentialanticanceractivity:beauvericinandotherconstituentsoftwoendophyticstrainsofFusariumoxysporum:J.Zhan,etal.;J.Nat.Prod.70,227(2007)
- AninhibitionstudyofbeauvericinonhumanandratcytochromeP450enzymesanditspharmacokineticsinrats:L.Mei,etal.;J.EnzymeInhib.Med.Chem.24,753(2009)
- InteractionsbetweenABC-transportproteinsandthesecondaryFusariummetabolitesenniatinandbeauvericin:R.Dornetshuber,etal.;Mol.Nutr.FoodRes.53,904(2009)
- BeauvericinandenniatinsH,IandMK1688arenewpotentinhibitorsofhumanimmunodeficiencyvirustype-1integrase:C.G.Shin,etal.;J.Antibiot.(Tokyo)62,687(2009)
- BeauvericinandochratoxinAgenotoxicityevaluatedusingthealkalinecometassay:singleandcombinedgenotoxicaction:M.S.Klarić,etal.;Arch.Toxicol.84,641(2010)
- NematicidalactivityofbeauvericinproducedbythefungusFusariumbulbicola:A.Shimada,etal.;Z.Naturforsch.C.65,207(2010)
- Beauvericinfromtheendophyticfungus,Fusariumredolens,isolatedfromDioscoreazingiberensisanditsantibacterialactivity:L.Xu,etal.;Nat.Prod.Commun.5,811(2010)
- TheFusariummycotoxinsenniatinsandbeauvericincausemitochondrialdysfunctionbyaffectingthemitochondrialvolumeregulation,oxidativephosphorylationandionhomeostasis:A.A.Tonshin,etal.;Toxicology276,49(2010)
- Beauvericininducederythrocytecellmembranescrambling:S.M.Qadri,etal.;Toxicology283,24(2011)
品牌介绍
Adipogen公司由三个子公司组成，分别是Adipogen,Inc.(韩国),AdipogenSA(瑞士)和 AdipogenCorporation(美国圣地亚哥)。总部设在美国，运营总部在瑞士利斯塔尔。Adipogen公司专门从事生命科学研究试剂的开发，如癌症、免疫、炎症、代谢疾病（糖尿病、肥胖）、干细胞和神经退行性疾病等领域。其重点关注开发创新优质的ELISA试剂盒。另外，也可提供抗体和蛋白产品，Adipogen拥有自己的化学实验室，致力于开发创新型小分子化合物。
联络我们
